Novo - Wegovy to Sell $4bn…This Year! (BUY, TP DKK1100 [900], 11 pgs)
Our proprietary Wegovy model built using the latest scrip data shows that Wegovy could sell $4bn this year in the US alone, which is double current consensus expectations. We now forecast $9bn in 2027 Wegovy sales & 24% EBIT growth this year putting us 8% higher than cons. Our Wegovy model accounts for the current scrip trajectory by dose (which is critical to the analysis), the closure of the Bridge programme, the current couponing, rebates & a multitude of other factors. We show that 2023 consensus implies volume only increases by 83% in 2023 & that weekly new pt starts decline from last week’s level despite the scrip trends. PT up to DKK1100.For access to the full note, please contact Naresh Chouhan ( )
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.